Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: Induction of cytotoxic T cells and specific tumor protection

International Journal of Cancer

Volumn 81, Issue 6, 1999, Pages 881-888

  Schäfer, Klaus ^a   Müller, Martin ^a   Faath, Stefan ^a   Henn, Annette ^a   Osen, Wolfram ^a   Zentgraf, Hanswalter ^a   Benner, Axel ^a   Gissmann, Lutz ^a,b   Jochmus, Ingrid ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b MediGene AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOSOL; CYTOTOXIC T LYMPHOCYTE; ENDOPLASMIC RETICULUM; FEMALE; GENE DELETION; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR IMMUNOLOGY; VIRUS RECOMBINANT; WART VIRUS;

EID: 0033044742     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990611)81:6<881::AID-IJC8>3.3.CO;2-K     Document Type: Article

References (33)

1. ALTMANN, A., JOCHMUS-KUDIELKA, I., FRANK, R., GAUSEPOHL, H., MOEBIUS, U., GISSMANN, L. and MEUER, S.C., Definition of immunogenic determinants of the human papillomavirus type 16 nucleoprotein E7. Europ. J. Cancer, 28, 326-333 (1992).
2. BENTON, C., SHAHIDULLAH, H. and HUNTER, J.A.A., Human papillomaviruses in the immunosuppressed. Papillomavirus Rep., 3, 23-26 (1992).
3. CHEN, L.P., THOMAS, E.K., HU, S.L., HELLSTRÖM, I. and HELLSTRÖM, K.E., Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc. nat. Acad. Sci. (Wash.), 88, 110-114 (1991).
4. COLEMAN, N., BIRLEY, H.D., RENTON, A.M., HANNA, N.F., RYAIT, B.K., BYRNE, M., TAYLOR ROBINSON, D. and STANLEY, M.A., Immunogenic events in regressing genital warts. Amer. J. clin. Pathol., 102, 768-774 (1994).
5. CROOK, T., MORGENSTERN, J.P., CRAWFORD, L. and BANKS, L., Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J., 8, 513-519 (1989).
6. DE GRUUL, T.D., BONTKES, H.J., STUKART, M.J., WALBOOMERS, J.M., REMMINK, A.J., VERHEIJEN, R.H., HELMERHORST, T.J., MEIJER, C.J. and SCHEPER, R.J., T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection. J. gen. Virol., 77, 2183-2191 (1996).
7. DE GRUIJL, T.D., BONTKES, J., WALBOOMERS, J.M.M., STUKART, M.J., DOEKHIE, F.S., REMMINK, A.J., HELMERHORST, T.J.M., VERHEIJEN, R.H.M., DUGGAN-KEEN, M.F., STERN, P.L., MEIJER, C.J.L.M. and SCHEPER, R.J., Differential T helper cell response to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. Cancer Res., 58, 1700-1706 (1998).
8. EVANS, E.M., MAN, S., EVANS, A.S. and BORYSIEWICZ, L.K., Infiltration of cervical cancer tissue with human papillomavirus-specific T-lymphocytes. Cancer Res., 57, 2943-2950 (1997).
9. FELTKAMP, M.C.W., SMITS, H.L., VIERBOOM, M.P.M., MINAAR, R.P., DE JONGH, B.M., DRIJFHOUT, M.J.W., TER SCHEGGET, J., MELIEF, C.J.M. and KAST, W.M., Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Europ. J. Immunol., 23, 2242-2249 (1993).
10. FELTKAMP, M.C.W., VREUGDENHIL, G.R., VIERBOOM, M.P.M., RAS, E., VAN DER BURG, S.H., TER SCHEGGET, J., MELIEF, C.J.M. and KAST, W.M., Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Europ. J. Immunol., 25, 2638-2642 (1995).
11. GREENSTONE, H.L., NIELAND, J.D., DE VISSER, K.E., DE BRUIJN, M.L.H., KIRNBAUER, R., RODEN, R.B.S., LOWY, D.R., KAST, W.M. and SCHILLER, J.T., Chimeric papillomavirus virus-like particles elicit anti-tumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. nat. Acad. Sci. (Wash.). 95, 1800-1805 (1998).
12. GRIFFITHS, J.C., HARRIS, S.J., LAYTON, G.T., BERRIE, E.L., FRENCH, T.J., BURNS, N.R., ADAMS, S.E. and KINGSMAN, A.J., Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion. J. Virol., 67, 3191-3198 (1993).
13. KADISH, A.S., HO, G.Y.F., BURK, R.D., WANG, Y., ROMNEY, S.L., LEDWIDGE, R. and ANGELETTI, R.H., Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J. nat. Cancer Inst., 89, 1285-1293 (1997).
14. KADISH, A.S., ROMNEY, S.L., LEDWIDGE, R., TINDLE, R., FERNANDO, G.J., ZEE, S.Y., VAN RANST, M.A. and BURK, R.D., Cell-mediated immune response to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific. J. gen. Virol., 75, 2277-2284 (1994).
15. LIN, K.-Y., GUARNIERI, F.G., STAVELEY-O'CARROLL, K.F., LEVITSKY, H.I., AUGUST, T., PARDOLL, D.M. and WU, T.C., Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res., 56, 21-26 (1996).
16. LJUNGGREN, H.G. and KÄRRE, K., Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J. exp. Med., 162, 1745-1757 (1985).
17. MENEGUZZI, G., CERNI, C., KIENY, M.P. and LATHE, R., Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology, 181, 62-69 (1991).
18. MÜLLER, M., GISSMANN, L., CRISTIANO, R.J., SUN, X.Y, FRAZER, I.H., JENSON, A.B., ALONSO, A., ZENTGRAF, H. and ZHOU, J., Papillomavirus capsid binding and uptake by cells from different tissues and species. J. Virol., 69, 948-954 (1995).
19. MÜLLER, M., ZHOU, J., REED, T.D., RITTMÜLLER, C., BURGER, A., GABELSBERGER, J., BRASPENNING, J. and GISSMANN, L., Chimeric papillomavirus-like particles. Virology, 234, 93-111 (1997).
20. NIMAKO, M., FIANDER, A.N., WILKINSON, G.W.G., BORYSIEWICZ, L.K. and MAN, S., Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Res., 57, 4855-4861 (1997).
21. PENG, S., FRAZER, I.H., FERNANDO, G.J. and ZHOU, J., Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology, 240, 147-157 (1998).
22. RESSING, M.E. and 12 OTHERS, Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A*0201 restricted E7-encoded epitope. Cancer Res., 56, 582-588 (1996).
23. RÖTZSCHKE, O., FALK, K., DERES, K., SCHILD, H., NORDA, M., METZGER, J., JUNG, G. and RAMMENSEE, H.G., Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature (Lond.), 348, 252-254 (1990).
24. SCHILLER, J.T. and RODEN, R.B.S., Papillomavirus-like particles. Papillomavirus Rep., 6, 121-128 (1995).
25. SPEIDEL, K., OSEN, W., FAATH, S., HILGERT, I., OBST, R., BRASPENNING, J., MOMBURG, F., HÄMMERLING, G.J. and RAMMENSEE, H.G., Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses. Europ. J. Immunol., 27, 2391-2399 (1997).
26. TAN, T.M.C. and TING, R.C.Y., In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Res., 55, 4599-4605 (1995).
27. TOWNSEND, A.R., ROTHBARD, J., GOTCH, F.M., BAHADUR, G., WRAITH, D. and MCMICHAEL, A.J., The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined by short synthetic peptides. Cell, 44, 959-968 (1986).
28. TSUKUI, T. and 19 OTHERS, Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res., 56, 3967-3974 (1996).
29. VON KNEBEL DOEBERITZ, M., OLTERSDORF, T., SCHWARZ, E. and GISSMANN, L., Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res., 48, 3780-3786 (1988).
30. VON KNEBEL DOEBERITZ, M., RITTMÜLLER, M.C., ZUR HAUSEN, H. and DÜRST, M., Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int. J. Cancer, 51, 831-834 (1992).
31. WATTS, C., Capture and processing of exogenous antigens for presentation on MHC molecules. Ann. Rev. Immunol., 15, 821-850 (1997).
32. ZHOU, J., GISSMANN, L., ZENTGRAF, H., MÜLLER, H., PICKEN, M. and MÜLLER, M., Early phase in the infection of cultured cells with papilloma virus virions. Virology, 214, 167-176 (1995).
33. ZUR HAUSEN, H., Papillomavirus infections - a major cause of human cancers. Biochem. biophys. Acta, 1288, 55-78 (1996).